1. A phase IV study of the safety of Synagis® (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis;Cohen,2005
2. A phase IV study of the safety of Synagis® (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract];Cohen,2005
3. American Academy of Pediatrics Committee on Infectious Diseases Policy Statement Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections Pediatrics
4. Role of respiratory syncytial virus in early hospitalization for respiratory distress of young infants with cystic fibrosis;Abman;Journal of Pediatrics,1988
5. Severe viral respiratory infections in infants with cystic fibrosis;Armstrong;Pediatric Pulmonology,1998